MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04411nam a22006617a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
200131s20202020 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1078-0432 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1158/1078-0432.CCR-19-1824 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
1078-0432.CCR-19-1824 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
31900276 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. |
| 251 ## - Source |
|---|
| Source |
Clinical Cancer Research. 26(6):1258-1266, 2020 03 15. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Clin Cancer Res. 26(6):1258-1266, 2020 03 15. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
Clin Cancer Res. 2020 Jan 03 |
| 253 ## - Journal Name |
|---|
| Journal name |
Clinical cancer research : an official journal of the American Association for Cancer Research |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2020 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2020 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
aheadofprint |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
ppublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2020-01-31 |
| 268 ## - Previous citation |
|---|
| -- |
Clinical Cancer Research. 2020 Jan 03 |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online from MWHC library: 1995 - present (after 1 year), Available in print through MWHC library: 1999 - February 2003 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: We show that quantitative assessments of CD8+ CD3+ PD-1+ T cells, % TAMs expressing PD-L1, and other T cell densities correlate with sarcoma response to pembrolizumab and improved PFS. Our findings support that multiple cell types present at the start of treatment may enhance tumor regression following anti-PD-1 therapy in specific advanced sarcomas. Efforts to confirm the activity of pembrolizumab in an expansion cohort of UPS/DDLPS patients are underway. Copyright (c)2020, American Association for Cancer Research. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
EXPERIMENTAL DESIGN: Pretreatment (n=78) and 8-week on-treatment (n=68) tumor biopsies were stained for PD-L1 and multiplex immunofluorescence panels. The density of positive cells was quantified to determine associations with anti-PD-1 response. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
PURPOSE: We recently reported a 17.5 % objective RECIST 1.1 response rate in a Phase II study of pembrolizumab in patients with advanced sarcoma (SARC028). The majority of responses occurred in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). We sought to determine whether we can identify immune features that correlate with clinical outcomes from tumor tissues obtained pre- and on-treatment. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: Patients that responded to pembrolizumab were more likely to have higher densities of activated T cells (CD8+ CD3+ PD-1+) and increased percentage of tumor associated macrophages (TAMs) expressing PD-L1 pre-treatment compared to non-responders. Pre-treatment tumors from responders also exhibited higher densities of effector memory cytotoxic T cells and regulatory T cells compared to non-responders. Additionally, higher density of cytotoxic tumor infiltrating T-cells at baseline correlated with a better progression-free survival (PFS). |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Antibodies, Monoclonal, Humanized/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*B7-H1 Antigen/ai [Antagonists & Inhibitors] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Biomarkers, Tumor/me [Metabolism] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Lymphocytes, Tumor-Infiltrating/im [Immunology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Programmed Cell Death 1 Receptor/ai [Antagonists & Inhibitors] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Sarcoma/im [Immunology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Soft Tissue Neoplasms/im [Immunology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Adolescent |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Adult |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged, 80 and over |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Antineoplastic Agents, Immunological/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Female |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Male |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Middle Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Sarcoma/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Sarcoma/pa [Pathology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Soft Tissue Neoplasms/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Soft Tissue Neoplasms/pa [Pathology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Survival Rate |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Treatment Outcome |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Young Adult |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
Washington Cancer Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Priebat, Dennis A |
| 790 ## - Authors |
|---|
| All authors |
Attia S, Bolejack V, Burgess M, Davis LE, Hu J, Keung EZ, Lazar AJ, Movva S, Okuno S, Parra Cuentas E, Priebat DA, Reed DR, Reinke DK, Reuben A, Riedel RF, Rodrigues-Canales J, Roland CL, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wang WL, Wargo JA |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1158/1078-0432.CCR-19-1824">https://dx.doi.org/10.1158/1078-0432.CCR-19-1824</a> |
| Public note |
https://dx.doi.org/10.1158/1078-0432.CCR-19-1824 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
